Novo Nordisk (NVO) repurchases 19.9M B shares under 2026 plan

Rhea-AI Filing Summary

Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company plans to repurchase B shares for up to DKK 15 billion over a 12-month period beginning 4 February 2026, including a sub-programme of up to DKK 11,200,000,010.45 running from 6 May 2026 to 1 February 2027.

As of 12 June 2026, Novo Nordisk has repurchased 19,884,179 B shares at an average price of DKK 264.99 per share, for a total of DKK 5,269,055,819. The company now holds 37,069,480 B shares as treasury shares, representing 0.8% of its 4,465,000,000 total A and B shares.

Key Figures

Total buyback programme size: DKK 15 billion Sub-programme capacity: DKK 11,200,000,010.45 Shares repurchased to date: 19,884,179 B shares +5 more

8 metrics

Total buyback programme size DKK 15 billion 12-month B share repurchase starting 4 February 2026

Sub-programme capacity DKK 11,200,000,010.45 B share repurchases from 6 May 2026 to 1 February 2027

Shares repurchased to date 19,884,179 B shares Cumulative repurchases since 4 February 2026 as of 12 June 2026

Average repurchase price DKK 264.99 per B share Average price on 19,884,179 B shares repurchased

Total repurchase value DKK 5,269,055,819 Transaction value of B shares bought since 4 February 2026

Treasury shares held 37,069,480 B shares Held as treasury shares, equal to 0.8% of share capital

Total share count 4,465,000,000 shares Total A and B shares including treasury shares

Recent daily repurchases 225,000 B shares per day Daily purchases from 8–12 June 2026 at DKK ~268–284

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, MAR, +1 more

5 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"Novo Nordisk owns a total of 37,069,480 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules")"

MAR regulatory

"in accordance with Article 5 of Regulation No 596/2014 ... (MAR)"

A market abuse regulation is a set of legal rules that forbid insider trading and deliberate manipulation of security prices and require fair disclosure of important company information. It works like a referee for markets, giving investors confidence that trades reflect real supply and demand rather than secret tips or engineered price moves, which helps protect the value of investments and the integrity of market prices.

ADRs financial

"Its ADRs are listed on the New York Stock Exchange (NVO)."

American Depositary Receipts (ADRs) are certificates issued by a U.S. bank that stand in for shares of a foreign company, allowing those shares to be bought and sold on U.S. stock exchanges in U.S. dollars. Think of an ADR as a local ticket representing a foreign stock: it makes trading, settlement, and tax reporting simpler for U.S. investors, but still exposes them to risks like currency moves, different accounting rules, and foreign corporate practices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/15/2026 - 07:43 AM Accepted by SEC EDGAR 06/15/2026 - 07:42 AM Learn about SEC filing dates

FAQ

What share buyback programme is Novo Nordisk (NVO) running in 2026?

Novo Nordisk is running a B share repurchase programme of up to DKK 15 billion over 12 months from 4 February 2026. This includes a sub-programme started 6 May 2026 under European Union Safe Harbour Rules.

How many Novo Nordisk (NVO) shares have been repurchased so far in 2026?

As of 12 June 2026, Novo Nordisk has repurchased 19,884,179 B shares since 4 February 2026. The average purchase price is DKK 264.99 per B share, for a total transaction value of DKK 5,269,055,819 under the programme.

What is the size of Novo Nordisk’s current sub-programme for share repurchases?

Under the sub-programme initiated on 6 May 2026, Novo Nordisk plans to repurchase B shares for up to DKK 11,200,000,010.45. This sub-programme runs from 6 May 2026 to 1 February 2027 as part of the broader DKK 15 billion plan.

How many Novo Nordisk (NVO) shares are held as treasury shares?

After the reported transactions, Novo Nordisk holds 37,069,480 B shares of DKK 0.10 as treasury shares. This represents 0.8% of the company’s total 4,465,000,000 A and B shares outstanding, including treasury shares.

What recent daily share repurchases has Novo Nordisk made under the programme?

Between 8 and 12 June 2026, Novo Nordisk repurchased 225,000 B shares each day. Average purchase prices ranged from DKK 268.40 to DKK 283.72 per B share, with daily transaction values around DKK 60–64 million.

On which exchanges are Novo Nordisk (NVO) shares traded?

Novo Nordisk’s B shares are listed on Nasdaq Copenhagen under the symbol Novo-B. Its American Depositary Receipts (ADRs) are listed on the New York Stock Exchange under the ticker NVO, giving access to U.S. investors.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

June 15, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 15 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 8 June 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	4,000,000		1,158,452,492
8 June 2026	225,000	275.43	61,972,755
9 June 2026	225,000	268.40	60,389,780
10 June 2026	225,000	272.47	61,305,543
11 June 2026	225,000	280.43	63,097,599
12 June 2026	225,000	283.72	63,837,660
Accumulated under the programme	5,125,000		1,469,055,829

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 37,069,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 12 June 2026, Novo Nordisk has since 4 February 2026 repurchased a total 19,884,179 B shares at an average share price of DKK 264.99 per B share equal to a transaction value of DKK 5,269,055,819.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. 

Contacts for further information

Media:
Ambre James-Brown		Liz Skrbkova (US)
+45 3079 9289		+1 609 917 0632
globalmedia@novonordisk.com		lzsk@novonordisk.com
Investors:
Michael Novod		Jacob Martin Wiborg Rode
+45 3075 6050		+45 3075 5956
nvno@novonordisk.com		jrde@novonordisk.com
Ida Schaap Melvold		Sina Meyer
+45 3077 5649		+45 3079 6656
idmg@novonordisk.com		azey@novonordisk.com
Alex Bruce		Christoffer Sho Togo Tullin
+45 3444 2613		+45 3079 1471
axeu@novonordisk.com		cftu@novonordisk.com
Frederik Taylor Pitter		Mads Berner Bruun
+1 609 613 0568		+45 3075 2936
fptr@novonordisk.com		mbbz@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 38 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 15, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer